
How Does IMBRUVICA® Work?
IMBRUVICA® is an Oral, Once-Daily MZL Medication That Works Differently Than Chemotherapy1
Marginal zone lymphoma (MZL) can sometimes be treated locally or systemically (throughout the body). A common initial systemic treatment for MZL is chemoimmunotherapy.2 Now, if you relapse and require additional therapy, you have another option with IMBRUVICA®.1
IMBRUVICA® (ibrutinib) blocks a protein in B cells called Bruton’s tyrosine kinase, or BTK. BTK signaling is needed for abnormal B cells to multiply and survive1
By blocking BTK, IMBRUVICA® may help move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs1,3
Because of how IMBRUVICA® works, it may cause side effects. A relationship between how IMBRUVICA® works and why it helps to treat certain diseases has not been clearly identified.1
References:
- IMBRUVICA® (ibrutinib) Prescribing Information.
- Ferreri AJM, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol. 2007;63(3):245-256.
- de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594.
- Genetics Home Reference. What genes are related to isolated growth hormone deficiency? https://ghr.nlm.nih.gov/condition/isolated-growth-hormone-deficiency#genes. Accessed April 26, 2019.